Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyCapital Bluecross Confocal Laser Endomicroscopy Co…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy MP 2.093

    Confocal Laser Endomicroscopy

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.093 alerts

    Get alerted when Policy MP 2.093 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the coverage stance for confocal laser endomicroscopy (CLE) for Capital Bluecross products and programs, describing clinical background, evidence summary, regulatory status, and coding guidance relevant to providers.

    Policy Summary
    PayerCapital Bluecross
    PolicyConfocal Laser Endomicroscopy
    Policy CodePolicy MP 2.093
    Change TypeClarified (removed code 88375)
    Effective DateJul 1, 2026
    Last ReviewMar 3, 2026
    Next Review Date
    Key ActionVerify prior authorization and member benefit rules for CLE services and note that codes 0397T and 43206 are investigational and not covered.
    SourceLink
    POLICY UPDATE CHANGES

    Removed code 88375 for Evicore.

    Investigationalcoverage stance

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0397T,43206
    investigational codes
    2FDA-cleared CLE system types
    81%-94% / 88%-95%reported sens/spec
    multiplepolicy reviews

    Coverage Determination

    General coverage determination

    Covered when ALL of the following are met

    Investigational stance: Use of confocal laser endomicroscopy is considered investigational due to insufficient evidence of improved net health outcomes.

    Policy declares CLE investigational for indications reviewed

    Procedure code 0397T is listed as investigational and is therefore not covered.

    Procedures billed with code 0397T are considered investigational and will be not covered when submitted for reimbursement.

    The evidence is insufficient to conclude that confocal laser endomicroscopy (CLE) improves net health outcomes for colorectal lesions, Barrett esophagus surveillance, assessment after endoscopic treatment, or other lesion‑based diagnostic indications; published systematic reviews and randomized trials report variable sensitivity and specificity and do not demonstrate that CLE reliably replaces standard biopsy‑based histopathology or established surveillance protocols.

    Procedure and Billing Codes

    Investigational / therefore not coveredCPTNot Covered
    0397TProcedure code listed as investigational
    43206Procedure code listed as investigational
    Investigational / Not covered procedure codesCPTNot Covered
    0397TProcedure code listed as investigational
    43206Procedure code listed as investigational

    Provider Responsibilities and Billing Guidance

    Prior Authorization

    Verify benefit variations and prior authorization

    This policy applies only to certain Capital Blue Cross programs and products that may have differing benefit terms; verify the member’s benefit plan and prior authorization requirements for confocal laser endomicroscopy (CLE) procedures before scheduling or performing services.

    • Confirm whether the member’s plan requires prior authorization and follow the plan-specific process (FEP PPO uses the FEP Medical Policy Manual).
    • Coverage determination depends on member benefit terms; preauthorization does not guarantee coverage for CLE because CLE is considered investigational.
    Prior Authorization

    Investigational codes — prior authorization/coverage impact

    Procedure codes 0397T and 43206 are listed as investigational and are not covered; obtain prior authorization for any related services per the member’s benefit terms and payer requirements when applicable.

    • Do not rely on coverage for services billed with 0397T or 43206 as these codes are investigational and not covered.

    Clinical Background and Evidence Summary

    Confocal laser endomicroscopy (CLE) provides real‑time, in vivo microscopic imaging of the mucosal epithelium during endoscopy using laser illumination and a pinhole detection system. Two FDA‑cleared approaches exist: endoscope‑based systems (integrated confocal probe at the endoscope tip) and probe‑based systems (miniaturized fiber‑optic probes passed through the working channel); CLE is used with contrast agents such as intravenous fluorescein to visualize cellular structures and has been studied to characterize colorectal lesions and to target biopsies during Barrett esophagus surveillance.

    Terms and Device Types

    Probe-based CLE — inv-16
    DefinitionProbe-based CLE: a miniaturized fiber optic probe placed through an endoscope working channel to provide microscopic imaging (e.g., Cellvizio).
    FDA-cleared exampleCellvizio (Mauna Kea Technologies) is a probe-based CLE system cleared by the FDA (F-600 cleared 2006; F400-v2 cleared 2015) intended for imaging internal microstructure via probes passed through a standard endoscope working channel.
    Technical noteProbe depth of view is approximately 120 μm and the viewing area is limited compared with endoscope-based systems; careful conventional endoscopy is needed to target areas for evaluation.
    Endoscope-based CLE — inv-17
    DefinitionEndoscope-based CLE: an endoscope with an integrated confocal probe at the tip providing microscopic visualization (e.g., Pentax Confocal Video Colonoscope historically).
    FDA-cleared example
    Policy Summary
    PayerCapital Bluecross
    PolicyConfocal Laser Endomicroscopy
    Policy CodePolicy MP 2.093
    Change TypeClarified (removed code 88375)
    Effective DateJul 1, 2026
    Last ReviewMar 3, 2026
    Next Review Date
    Key ActionVerify prior authorization and member benefit rules for CLE services and note that codes 0397T and 43206 are investigational and not covered.
    SourceLink
    On This Page
    Coverage DeterminationProcedure and Billing CodesProvider Responsibilities and Billing GuidanceClinical Background and Evidence SummaryTerms and Device Types
  1. For other CLE services, providers should follow member benefit prior authorization procedures before performing the service.
  2. Step Therapy

    Standard surveillance remains

    Continue to follow standard surveillance protocols for Barrett esophagus (for example, endoscopic surveillance every 3–5 years for nondysplastic BE and random 4‑quadrant biopsies every 2 cm per AGA recommendations); CLE is not established as a replacement for these standard surveillance methods.

    • Perform recommended random 4‑quadrant biopsies every 2 cm with white‑light endoscopy in individuals without known dysplasia as per AGA guidance.
    • CLE may be used in research or investigational contexts but should not supplant guideline‑recommended surveillance biopsy protocols.
    Note

    Provider-impact highlight

    No additional provider-action text is specified for this placeholder in the source; follow the policy’s documented requirements above (investigational stance, coding exclusions, and benefit verification) when considering CLE procedures.

    • CLE is considered investigational and lacks sufficient evidence of net health outcome benefit.
    • Procedures billed with 0397T or 43206 are investigational and not covered.
    Documentation Required

    Documentation and coding note

    Coding lists in this policy may not be exhaustive and coverage is determined by the member’s benefit terms; document medical necessity and relevant clinical findings in the medical record per applicable coding guidance and member benefits.

    • Maintain documentation that justifies medical necessity per the member’s plan.
    • Use up‑to‑date coding resources; presence of a code in this policy does not guarantee coverage.
    Billing Rule

    Reimbursement and documentation note

    Not all services that are covered under a member’s benefit are eligible for separate reimbursement; follow member benefit information and payer reimbursement rules when billing for CLE‑related services.

    • Confirm whether the service is eligible for separate reimbursement under the member’s plan before billing.
    • Adhere to payer billing rules and the member’s coverage terms to avoid improper claims.
    Denial Risk

    Investigational — potential denial

    Use of confocal laser endomicroscopy is considered investigational; procedures using CLE may be denied. Providers should verify benefits and avoid billing investigational codes (0397T, 43206) for covered claims.

    • Document the clinical rationale in the chart; however, investigational designation may still lead to claim denial.
    • Discuss alternative, guideline‑recommended approaches when CLE is investigational for the indication.
    Denial Risk

    Investigational procedure codes — denial risk

    Claims billed with procedure codes 0397T or 43206 will be considered investigational and are not covered; using these codes may result in denial of the claim.

    • Do not bill 0397T or 43206 for services expected to be covered—these codes are listed as investigational and not covered.
    • Obtain prior authorization for other CLE services per member benefit terms, but note that these two codes are specifically excluded from coverage.
    Pentax Confocal Video Colonoscope (EC-3870CIK) is an endoscope-based CLE system cleared by the FDA (2004) to provide optical and microscopic visualization of the lower GI tract; this device is no longer commercially available.
    Technical noteEndoscope-based CLE has a greater depth of view (up to ~250 μm) and larger maximum examined area (up to ~700 μm) compared with probe-based systems, but still a limited field requiring targeted conventional endoscopy.
    Confocal laser endomicroscopy (CLE) — inv-18
    DefinitionConfocal laser endomicroscopy (CLE) is a probe- or endoscope-based endoscopic imaging modality that provides real-time, in vivo microscopic visualization of mucosal tissue to aid diagnosis and guide targeted biopsy.
    Alternative namesAlso called confocal fluorescent endomicroscopy or optical endomicroscopy.
    PrincipleCLE uses low-power laser illumination and a pinhole detection system so that illumination and collection are in the same focal plane, improving spatial resolution of microscopic images.
    Regulatory statusTwo CLE device approaches (probe-based and endoscope-based) have been cleared by the FDA through 510(k) submissions.